

Kardiologia Polska

The Official Peer-reviewed Journal of the Polish Cardiac Society since 1957

Online first

This is a provisional PDF only. Copyedited and fully formatted version will be made available soon

ISSN 0022-9032 e-ISSN 1897-4279

Zero-contrast TAVI: A novel alternative for a difficult patient population

Authors: Łukasz Pyka, Krzysztof Wilczek, Anna Kwiecień, Tomasz Niklewski, Tomasz

Hrapkowicz, Mariusz Gasior

Article type: Clinical vignette

Received: March 24, 2024

Accepted: June 24, 2024

Early publication date: July 5, 2024

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

Zero-contrast TAVI: A novel alternative for a difficult patient population

Short title: Zero-contrast TAVI

Łukasz Pyka¹, Krzysztof Wilczek¹, Anna Kwiecień², Tomasz Niklewski², Tomasz Hrapkowicz²,

Mariusz Gasior¹

¹3rd Department of Cardiology, Faculty of Medical Sciences in Zabrze, Medical University of

Silesia, Katowice, Poland

²Department of Cardiac Surgery, Transplantology and Vascular Surgery, Faculty of Medical

Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

Correspondence to:

Łukasz Pyka

3rd Department of Cardiology.

Silesian Center for Heart Diseases,

Faculty of Medicine in Zabrze,

Medical University of Silesia,

Skłodowskiej-Curie 9, 41–800 Zabrze, Poland,

phone: +48 32 373 38 60,

e-mail: l.t.pyka@gmail.com

Transcatheter aortic valve implantation (TAVI) is the current state-of-the-art method of

treatment of severe aortic stenosis in high-risk patients, as well as a viable alternative for certain

mid- and low-risk patients [1, 2]. Preparation of the procedure requires a computed tomography

(CT)-angiogram of the aorta and usually coronary angiography. The procedure itself is contrast

guided. In this high-risk population, a significant percentage of patients suffer from chronic

kidney disease [3] which had been shown to be the most important risk factor of contrast

induced nephropathy (CIN), leading to significantly impaired outcomes [4]. Studies have

shown, that in TAVI patients with chronic kidney disease or at risk of CIN, zero-contrast TAVI

procedures may be a viable option [5].

A 70-year-old male patient with a left ventricular ejection fraction of 25%, severe aortic

stenosis with an area of 0.8 mm² and a mean gradient of 41 mm Hg was admitted to our

institution. The patient was 10-years post coronary artery bypass grafting and had a recently implanted cardioverter-defibrillator. During initial assessment before TAVI in another center a coronary angiography was performed, showing multivessel coronary artery disease with patent LIMA and venous grafts with no indication for further revascularization. Subsequently CIN occurred and a persistent decrease of eGFR to 20–23 ml/min/1.73 m² was observed. Therefore, we have decided to perform a zero-contrast TAVI procedure.

The assessment of access site was performed with doppler ultrasound (showing no significant lesions), followed by a non-contrast CT, which revealed relatively straightforward femoral access with limited calcifications (Supplementary material, *Figure S1*). We have considered nuclear magnetic resonance imaging (NMR), but due to satisfactory CT and doppler images we have decided to confine NMR to the heart and ascending aorta. A normal three cusp anatomy was confirmed in CT, NMR and echocardiography (Supplementary material, *Figure S2*). Aortic angulation, coronary ostia heights and selection of implant view were based on noncontrast CT (Supplementary material, *Figure S3*). The quantification of aortic valve annulus was challenging, as some discrepancies were present in the utilized modalities (3D transesophageal echocardiography [TEE] — 24–25 mm; CT 23.5 mm; NMR 26 mm). Nonetheless, all of the measurements were within the size of a 26 mm Edwards Sapien S3 Ultra valve (Supplementary material, *Figure S4*).

For the procedure the patient was in general anesthesia. Right femoral access with surgical cutdown was utilized in order to optimize access site management. The procedure was under permanent TEE control. A pigtail catheter was introduced to the non-coronary cusp from radial access. Crossing of the valve and introduction of an extra-stiff Confida guidewire was performed. Finally, an AL 1.0 catheter with a protruding wire was introduced to the left coronary cusp from left femoral access (Supplementary material, *Figure S5*). A balloon valvuloplasty was performed with a 25 × 40 mm valvuloplasty balloon. A notch during inflation was observed on the balloon, which in our opinion confirmed correct zero-contrast sizing of the annulus (Supplementary material, *Figure S6*). Valve positioning and implantation were guided by the location of catheters in coronary cusps (Supplementary material, *Video S1*). Final echo showed optimal TAVI result with no paravalvular leak and a mean gradient of 7 mm Hg. The patient was discharged after 3 days of uncomplicated in-hospital stay.

In three-month follow-up the patient remains asymptomatic (New York Heart Association I, Canadian Cardiovascular Society I), with stable renal function, showing that zero-contrast TAVI may be a viable treatment option in these extremely complicated patients.

Supplementary material

Supplementary material is available at https://journals.viamedica.pl/polish_heart_journal.

Article information

Conflict of interest: None declared.

Funding: None.

Open access: This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, which allows downloading and sharing articles with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially. For commercial use, please contact the journal office at polishheartjournal@ptkardio.pl

REFERENCES

- Mack MJ, Leon MB, Smith CR, et al. PARTNER 1 trial investigators. 5-year outcomes
 of transcatheter aortic valve replacement or surgical aortic valve replacement for high
 surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial.
 Lancet. 2015; 385(9986): 2477–2484, doi: 10.1016/S0140-6736(15)60308-7, indexed
 in Pubmed: 25788234.
- Galper BZ, Chinnakondepalli KM, Wang K, et al. PARTNER Investigators. Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial. Circulation. 2023; 147(21): 1594–1605, doi: 10.1161/CIRCULATIONAHA.122.062481, indexed in Pubmed: 37154049.
- 3. Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2020; 76(21): 2492–2516, doi: 10.1016/j.jacc.2020.09.595, indexed in Pubmed: 33213729.
- 4. Jäckel M, Keller S, Prager EP, et al. The impact of transcatheter aortic valve implantation planning and procedure on acute and chronic renal failure. Cardiol J. 2023; 30(2): 247–255, doi: 10.5603/CJ.a2021.0057, indexed in Pubmed: 34312832.
- 5. Freire AF, Nicz PF, Ribeiro HB, et al. Non-contrast transcatheter aortic valve implantation for patients with aortic stenosis and chronic kidney disease: a pilot study. Front Cardiovasc Med. 2023; 10: 1175600, doi: 10.3389/fcvm.2023.1175600, indexed in Pubmed: 37388643.




Figure 1. Main aspects of the zero-contrast transcatheter aortic valve implantation procedure